Clinical Trials Logo

Adenocarcinoma - GEJ clinical trials

View clinical trials related to Adenocarcinoma - GEJ.

Filter by:
  • None
  • Page 1

NCT ID: NCT06059495 Recruiting - Clinical trials for Gastric Adenocarcinoma

Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

DEWI
Start date: December 18, 2023
Phase: Phase 2
Study type: Interventional

This phase II study will evaluate dostarlimab with a watch-and-wait approach for patients with localized mismatch repair deficiency (dMMR)/microsatellite instability (MSI) gastric or oeso-gastric junction adenocarcinoma. The goal of the study is to determine whether the surgery could be avoided in patients with localized dMMR/MSI-H gastric/OGJ adenocarcinoma with complete response at endoscopy and biopsies free of tumoral cells after treatment with dostarlimab, with a watch-and-wait approaches.

NCT ID: NCT05315830 Recruiting - Clinical trials for Adenocarcinoma of the Stomach

A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Start date: March 7, 2022
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, clinical study to evaluate the safety of HER2 tumor vaccine injection alone/in combination with standard of care chemotherapy in patients with HER2/neu overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, pharmacokinetics and of HER2 tumor vaccine.

NCT ID: NCT04984733 Recruiting - Cancer of Esophagus Clinical Trials

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer

ELEVATE
Start date: September 28, 2021
Phase: Phase 2
Study type: Interventional

An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is MGMT deficient.

NCT ID: NCT04014075 Completed - Clinical trials for Adenocarcinoma - GEJ

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Start date: November 26, 2019
Phase: Phase 2
Study type: Interventional

This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer. They must have human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) cancer: - that cannot be removed surgically - that has moved to other parts of the body - that got worse during or after treatment that included trastuzumab The study will enroll about 80 participants. Sites will be in North America and the European Union.